Brentuximab vedotin in the treatment of a patient with refractory Hodgkin disease and Proteus syndrome – a case report and discussion

Clinical Case Reports

Natalia Myakova¹  Nadezhda Smirnova¹  Dmitry Evstratov¹  Yulia Abugova¹  Dmitry Balashov¹  Yulia Diakonova¹  Dmitry Konovalov¹  Yulia Skvortsova¹ 

[1] Federal Center for Pediatric Hematology, Oncology and Immunology, Named by D. Rogachev, Moscow, Russia

关键词: Brentuximab vedotin;    children;    Hodgkin lymphoma;    Proteus syndrome;   

DOI  :  10.1002/ccr3.297

来源: Wiley

【 摘 要 】

Key Clinical Message

Treatment of patients with refractory Hodgkin lymphoma is a significant issue. We report a patient with Proteus syndrome and relapsed Hodgkin lymphoma, whose remission was finally achieved after brentuximab vedotin therapy, allowing her to receive a haploidentical stem cell transplant. The possible relationship between both disorders was discussed.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.